Reply
To the Editor-Thackray and Field [1] raise 4 points that they believe explain why our recent study [2] failed to document the virologic superiority of famciclovir over valacyclovir that they described in several reports and numerous abstracts.
First, the route of infection did differ, as we acknowledged in our Discussion section [2] . They argue, however, that infection of the cornea (as opposed to the ear pinna in their model system) would favor direct uptake of virus into the axons, eliminating the opportunity a drug started 24 h later might have to limit viral amplification in the ganglia. We believe that any such aspect of our model system is overstated. In our studies, virus titers in tissues continued to rise for some days after the start of treatment (figure 3 in [2] ). Thus, there remained ample opportunity for viral replication to be affected by the drugs. Nonetheless, we failed to observe any differential benefit of famciclovir. Moreover, Thackray and colleagues [3] [4] [5] reported experiments in which they delayed treatment even further and still observed superiority of famciclovir.
Second, Thackray and Field [1] are concerned about the virus inoculum that we used, because it was associated with universal mortality in the absence of treatment. It is true that no positive controls remained with which to compare the effects of treatment on latency and reactivation; however, untreated animals survived long enough for us to observe that famciclovir and valacyclovir were equivalent in virologic outcome measures of the acute infection.
Third, with regard to a rebound of virus titers, we disagree that there is a "variance with the results published" [1] . It has been our experience that the time points chosen are more than sufficient to track the spread of herpes simplex virus (HSV) from the eye to the trigeminal ganglia and into the brain. With the chosen time points, we saw the spread of virus through these tissues. Moreover, we detected no differences in the effect of either drug during the testing period. Obviously, for a true rebound to occur, the initial infection first must be cleared. Clearance was beginning to occur by the final time point, postinfection day 11. In an immunosuppression model, Field et al. [3] tested ear and brain samples on intermittent days and still detected a rebound of virus titers.
Fourth, we claimed equivalence of both drugs in "terminating ganglionic infection" [2] , by which we meant the presence of infectious virus in the tissue. Despite their claim to the contrary, Thackray and Field [4, 5] reported that famciclovir was superior in reducing the amount of both infectious and latent virus in ganglia and in "preventing the establishment of latency" (Discussion in [4] ; Introduction and Discussion in [5] ). We agree that each animal model has its own advantages and disadvantages. We believe, from our own data, that famciclovir and valacyclovir are equivalent for the acute treatment of HSV infections and will continue to believe so until a welldesigned clinical trial proves otherwise.
Questions about Results Reported with Potent Antiretroviral Therapy for Human Immunodeficiency Virus Type 1 Infection
To the Editor-Zaunders et al. [1] report the clearance rates of plasma human immunodeficiency virus (HIV) type 1 RNA and peripheral blood HIV-1 DNA levels, the phenotypic profiles of CD4 and CD8 lymphocytes, and anti-HIV-1 antibody levels in patients treated for 52 weeks with antiretroviral therapy (combination of zidovudine, lamivudine, and indinovir). Therapy was begun during primary HIV-1 infection (PHI). Results were compared with results for HIV-1-uninfected subjects, un-treated patients with PHI, and patients with established HIV-1 infection. The data reported raise several questions.
First, by week 8 a similar decrease in peripheral blood HIV DNA levels was observed in both treated and untreated patients. What was the reason for the decrease in untreated patients, and why was there no difference in the decreases in the 2 groups?
Second, reverse-transcriptase inhibitors prevent reverse transcription (RT) of HIV RNA into HIV DNA, whereas protease inhibitors render newly produced virions noninfectious. Furthermore, according to the most recent model of HIV-1 pathogenesis reported by Ho et al. [2] and Wei et al. [3] , productively infected lymphocytes have a half-life of ∼1.6 days. However, Zaunders et al. [1] found continued expression of viral antigens. In this case, one would expect the HIV DNA to increase or at least to remain stable in the untreated patients with PHI and to decrease rapidly in treated patients. What is the explanation for their findings that treatment "had little direct effect on HIV- Sixth, given that the aim of the study was to compare treatment between patients with PHI and "HIV-1-uninfected subjects, untreated PHI patients, and patients with established HIV-1 infection, [1, p. 320 ]" why, with the exception of the lymphocyte profiles, were no data presented on the HIV-1-uninfected subjects and the patients with established HIV-1 infection?
Finally, for the measurement of the HIV RNA, Zaunders et al. [1] 
